G Kranz
Overview
Explore the profile of G Kranz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elwischger K, Kasprian G, Weber M, Meyerspeer M, Linder C, Auff E, et al.
J Neurol Sci
. 2014 Jul;
344(1-2):76-9.
PMID: 25023196
Objective: A precise knowledge of the spread of botulinum toxin (BoNT) in muscle tissue is required to efficiently access endplate zones and increase BoNT's therapeutic efficacy. Here, we aimed to...
2.
Baldinger P, Kranz G, Hoflich A, Savli M, Stein P, Lanzenberger R, et al.
Nervenarzt
. 2012 Feb;
84(1):14-9.
PMID: 22318360
Hormonal fluctuations during the perimenopausal transition lead to physical discomfort but are also frequently accompanied by mood swings, depressive symptoms, anxiety and sleeping disorders. The important role of the neurotransmitter...
3.
Kranz G, Paul A, Voller B, Posch M, Windischberger C, Auff E, et al.
Br J Dermatol
. 2010 Nov;
164(1):176-81.
PMID: 21039405
Background: Mouse units (mU) are used for quantification of the biological activity of botulinum A and B toxin preparations. However, in human tissue, mU values between preparations are not equivalent...
4.
Kranz G, Shamim E, Lin P, Kranz G, Hallett M
Neurology
. 2010 Oct;
75(16):1465-71.
PMID: 20956792
Background: Benign essential blepharospasm (BEB) is a common form of focal dystonia. Besides pathology in the basal ganglia, accumulating evidence suggests pathologic changes in the anterior cingulate cortex (ACC). Methods:...
5.
Kranz G, Shamim E, Lin P, Kranz G, Voller B, Hallett M
Neurology
. 2009 Dec;
73(23):2031-6.
PMID: 19996078
Background: Traditionally, benign essential blepharospasm (BEB) is considered a disorder caused by basal ganglia dysfunction. Electrophysiologic and brain imaging studies suggest pathologic changes in excitability in the primary motor cortex...
6.
Kranz G, Sycha T, Voller B, Kranz G, Schnider P, Auff E
Neurology
. 2008 Jan;
70(2):133-6.
PMID: 18180443
Background: Complete secondary therapy failure due to antibodies against botulinum toxin A (BoNT/A-ABs) may raise extensive treatment difficulties. We tested whether neutralizing BoNT/A-ABs can be detected in dystonic patients with...
7.
Voller B, Sycha T, Gustorff B, Kranz G, Auff E
Neurology
. 2006 May;
66(9):1458-9.
PMID: 16685761
No abstract available.
8.
Schnider P, Moraru E, Kittler H, Voller B, Kranz G, Auff E
Wien Klin Wochenschr
. 2004 Oct;
113 Suppl 4:36-41.
PMID: 15506051
Introduction: Botulinum A toxin (BTX-A) acts primarily at peripheral cholinergic synapses, inhibiting the release of acetylcholine. Initially it has been used to block the neuromuscular junction in focal dystonic and...
9.
Sycha T, Kranz G, Auff E, Schnider P
J Neurol
. 2004 Mar;
251 Suppl 1:I19-30.
PMID: 14991339
Background: Botulinum neurotoxin (BoNT) is used to treat various neurological disorders associated with pathologically increased muscle tone. Botulinum toxin inhibits the release of the neurotransmitter acetylcholine at the neuromuscular junction...
10.
Schnider P, Moraru E, Kittler H, Binder M, Kranz G, Voller B, et al.
Br J Dermatol
. 2001 Sep;
145(2):289-93.
PMID: 11531794
Background: The blocking action of botulinum toxin type A (BTX-A) on cholinergically innervated sweat glands has been used successfully to treat patients with focal hyperhidrosis. Objectives: To investigate the long-term...